Hoeh B, Würnschimmel C, Flammia RS, et al. - Findings demonstrate an increase in chemotherapy rates, from 5% to 25% over time, in metastatic prostate cancer (mPCa) patients, with a concomitant increase in survival.

• The Surveillance, Epidemiology, and End Results database (2004–2016) was used to select 19,913 patients with de novo mPCa.

• Patients were categorized between historical (2004–2013) vs contemporary (2014–2016).

• Chemotherapy-exposed patients were 1,838; of those, 903 were historical, and 905 were contemporary.

• Median overall survival was not reached vs 24 months in contemporary group vs historical patients, respectively, (hazard ratio [HR]: 0.55).

• A HR of 0.55 was obtained following propensity score matching and additional multivariable adjustment.